Disease · HP_0003074

Hyperglycemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Hyperglycemia. Diseases, record HP_0003074. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003074

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Hyperglycemia; Open Targets
Open Targets ID: HP_0003074; Open Targets
Other names: High blood glucose, High blood sugar, hyperglycaemia; Open Targets
Disease Ontology: DOID:4195; Disease Ontology
NCI Thesaurus: C26797; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 18 of its 51 drugs, from ClinicalTrials.gov; Open Targets

Drugs51

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INSULIN HUMAN	CHEMBL1201631	Protein	Phase 3	ClinicalTrials.gov	32	32	32	Drugs and targets
INSULIN GLARGINE	CHEMBL1201497	Protein	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
INSULIN LISPRO	CHEMBL1201538	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DAPAGLIFLOZIN	CHEMBL429910	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GLUCAGON	CHEMBL5314341	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LINAGLIPTIN	CHEMBL237500	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SITAGLIPTIN	CHEMBL1422	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VILDAGLIPTIN	CHEMBL142703	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CAGRILINTIDE	CHEMBL4802169	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 51

See all 51 drugs

Targets80

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	8	Insulin receptor agonist	Phase 3	https://conductscience.org/library/genes/3643	Drugs and targets
DPP4	Dipeptidyl peptidase 4	5	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	2	Sulfonylurea receptor 1, Kir6.2 blocker	Phase 2	https://conductscience.org/library/genes/6833	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	2	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	2	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	2	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 3	https://conductscience.org/library/genes/56901	Drugs and targets
GCGR	Glucagon receptor	2	Glucagon receptor agonist; Glucagon receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2642	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	2	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	2	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 3	https://conductscience.org/library/genes/2820	Drugs and targets

1 to 10 of 80

See all 80 targets

Trials72

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01369069	Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial	Phase 3	1,151	2019-12-16	Acute Ischemic Stroke, Diabetes, Hyperglycemia	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT01565941	Heart And Lung Failure - Pediatric INsulin Titration Trial	Phase 3	713	2017-12-11	Heart Failure, Respiratory Failure	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00900146	Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients	Phase 2/3	556	2012-02-20	Diabetes Mellitus, Type 2	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00621140	Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control	Phase 3	503	2011-06-07	Diabetes Mellitus, Type 2	LINAGLIPTIN	Its record names the disease	ClinicalTrials.gov
NCT00353431	Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia	Not applicable	130	2012-05-08	Hyperglycemias	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT01621776	Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia	Not applicable	107	2013-09-13	Type 1 Diabetes	INSULIN GLULISINE, INSULIN LISPRO	Its record names the disease	ClinicalTrials.gov
NCT01033773	Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)	Not applicable	86	2020-10-05	Type 2 Diabetes Mellitus	INSULIN HUMAN, METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT01217112	GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes	Phase 2	62	2014-01-20	Dyslipidemias, Diabetes Mellitus, Type 2	CANNABIDIOL, TETRAHYDROCANNABIVARIN	Its record names the disease	ClinicalTrials.gov
NCT00936741	An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome	Phase 3	30	2014-04-02	Cushing's Syndrome	MIFEPRISTONE	Its record names the disease	ClinicalTrials.gov
NCT01186003	Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy	Not applicable	30	2021-12-07	Diabetes	INSULIN DETEMIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 72

See all 72 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL)	15 of 581	0 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Death	54 of 581	65 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: deaths from any cause	54 of 581	65 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable Modified Rankin Scale (Yes/No)	119 of 581	123 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: serious adverse events	209 of 581	198 of 570	1,151	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable Barthel Index	271 of 491	261 of 477	968	NCT01369069	Trial comparisons
IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable NIHSS	152 of 348	166 of 371	719	NCT01369069	Trial comparisons
Tight Glycemic Control 1 (TGC-1) vs Tight Glycemic Control 2 (TGC-2): Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)	13 of 349	1 of 349	698	NCT01565941	Trial comparisons
Tight Glycemic Control 1 (TGC-1) vs Tight Glycemic Control 2 (TGC-2): Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)	26 of 349	29 of 349	698	NCT01565941	Trial comparisons
Tight Glycemic Control 1 (TGC-1) vs Tight Glycemic Control 2 (TGC-2): 90-day Hospital Mortality	52 of 349	40 of 349	698	NCT01565941	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37405785	RESULT	1	PubMed
37380728	RESULT	1	PubMed
34590159	RESULT	1	PubMed
33915345	RESULT	1	PubMed
31334795	RESULT	1	PubMed
27964837	RESULT	1	PubMed
25881192	RESULT	1	PubMed
24401049	RESULT	1	PubMed
22223765	RESULT	1	PubMed
20883542	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0003074

GET https://conductscience.org/api/diseases/v1/HP_0003074/drugs?page=2

API reference For AI assistants